Barclays analyst Tracy Benguigui raised the firm’s price target on Allstate to $128 from $108 and keeps an Equal Weight rating on the shares. On Nov. 1, Allstate shared its intent to sell its Health & Benefits business in 2024, which could potentially command a $3.8B-$4.4B illustrative valuation, the firm pointed out in a research note on Friday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALL: